Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml
Klin Monbl Augenheilkd 2021; 238(06): 711-714
DOI: 10.1055/a-1306-0854
DOI: 10.1055/a-1306-0854
Der interessante Fall
Beidseitige Nivolumab-assoziierte Vogt-Koyanagi-Harada-artige Uveitis bei einem Patienten mit metastasiertem Nierenzellkarzinom
Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma
Einleitung
Mit dem vermehrten Einsatz von Immun-Checkpoint-Inhibitoren in der Behandlung verschiedener, häufig bisher nicht therapierbarer Tumorerkrankungen treten immer häufiger autoimmune Nebenwirkungen auf. Hierzu zählt auch die Uveitis. Die medikamenteninduzierte Uveitis stellt somit ein seltenes, jedoch zunehmend auftretendes Krankheitsbild dar.
Publication History
Received: 06 June 2020
Accepted: 05 October 2020
Article published online:
04 January 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Dalvin LA, Shields CL, Orloff M. et al. Checkpoint inhibitors immune therapy: systemic indications and ophthalmic side effects. Retina 2018; 38: 1063-1078 doi:10.1097/IAE.0000000000002181
- 2 Heinzerling L, de Toni E, Schett G. et al. Checkpoint-Inhibitoren – Diagnostik und Therapie von Nebenwirkungen. Dtsch Arztebl Int 2019; 116: 119-126 doi:10.3238/arztebl.2019.0119
- 3 Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 2019; 31: 319-322 doi:10.1016/j.joco.2019.05.002
- 4 Michel M, Sun MM, Levinson RD, Filipowicz A. et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm 2020; 28: 217-227 doi:10.1080/09273948.2019.1577978
- 5 Obata S, Saishin Y, Teramura K. et al. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 2019; 10: 67-74 doi:10.1159/000496682
- 6 Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 2017; 5: 694-700 doi:10.1002/ccr3.911
- 7 Mihailovic N, Dyballa J, Herz S. et al. Vogt-Koyanagi-Harada-artige Uveitis unter Immun-Checkpoint-Inhibitor-Therapie beim metastasierten malignen Melanom. Ophthalmologe 2020; 117: 467-471 doi:10.1007/s00347-019-00963-z
- 8 Liu X, Wang Z, Zhao C. et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer 2020; 11: 810-818 doi:10.1111/1759-7714.13327
- 9 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768 doi:10.1200/JCO.2017.77.6385
- 10 Shulgin B, Kosinsky Y, Helmlinger G. et al. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology 2020; 9: 1748982 doi:10.1080/2162402X.2020.1748982